ERYTECH confirme son intention de déposer une demande de BLA pour eryaspase dans le traitement des patients atteints de LAL hypersensible

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy